{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:12:21Z","timestamp":1772694741037,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cannabis (\u0394<jats:sup>9<\/jats:sup>-THC) is the most commonly consumed illicit drug. The Agricultural Improvement Act of 2018 removed hemp, a strain of <jats:italic>Cannabis sativa<\/jats:italic>, as a controlled substance. This law allowed the plant to be processed into its components, which contain &amp;lt;0.3% \u0394<jats:sup>9<\/jats:sup>-THC. As a result, delta-8-tetrahydrocannabinol (\u0394<jats:sup>8<\/jats:sup>-THC), a federally unregulated substance, grew in popularity in 2020. \u0394<jats:sup>8<\/jats:sup>-THC is readily available in most gas stations or head shops and may be considered harmless by patients. However, an increasing number of patients admitted for psychiatric hospitalization report use, with limited literature on the effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentations<\/jats:title><jats:p>This case report describes three individual cases of patients who required admission to a university psychiatric hospital after the regular use solely of \u0394<jats:sup>8<\/jats:sup>-THC. All three patients developed psychotic and paranoid symptoms concurrently with the use of \u0394<jats:sup>8<\/jats:sup>-THC, with a severity exceeding their previous historical presentations. The presenting psychotic symptoms were also atypical for all three patients. New-onset violence and visual hallucinations were noted in two of the patients, one patient with no previous psychiatric history and one patient while on a therapeutic dose of his antipsychotic. In the third case, a new onset of bizarre, fixed delusions of puppies dissolving in the bathtub developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report adds to the limited body of evidence on \u0394<jats:sup>8<\/jats:sup>-THC documenting a temporal association between \u0394<jats:sup>8<\/jats:sup>-THC use and the development of psychotic symptoms. A strong body of research already correlates the continued use of \u0394<jats:sup>9<\/jats:sup>-THC with psychosis, and \u0394<jats:sup>8<\/jats:sup>-THC acts at the same CB<jats:sub>1<\/jats:sub> and CB<jats:sub>2<\/jats:sub> receptors as \u0394<jats:sup>9<\/jats:sup>-THC. Therefore, it is hypothesized that \u0394<jats:sup>8<\/jats:sup>-THC may have similar adverse psychiatric effects as \u0394<jats:sup>9<\/jats:sup>-THC. These conclusions are not without speculation, due to the need for self or collateral-reporting of \u0394<jats:sup>8<\/jats:sup>-THC use as urine drug screening cannot distinguish \u0394<jats:sup>8<\/jats:sup>-THC from \u0394<jats:sup>9<\/jats:sup>-THC, and the patients' symptoms could be explained by medication non-adherence and primary psychotic disorders. However, physicians should be encouraged to gather a specific history of \u0394<jats:sup>8<\/jats:sup>-THC use and treat patients with \u0394<jats:sup>8<\/jats:sup>-THC-related intoxication and symptoms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1103123","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:24:59Z","timestamp":1676877899000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Delta-8-THC association with psychosis: A case report with literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Chelsea R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley G.","family":"Burk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Fargason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","article-title":"Potency trends of \u03949-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008","volume":"55","author":"Mehmedic","year":"2010","journal-title":"J Forensic Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med."},{"key":"B3","first-page":"29","volume-title":"The Cannabis-Psychosis Link: Mind Your Mind","author":"Lynch","year":"2012"},{"key":"B4","first-page":"428","article-title":"Growing industry: the 2018 farm bill and delta-8 THC legalization","volume":"22","author":"Osborne","year":"2021","journal-title":"Wake Forest J Bus Intell Prop Law."},{"key":"B5","unstructured":"2018"},{"key":"B6","first-page":"48950","article-title":"Schedules of controlled substances: placement in schedule V of certain FDA-approved drugs containing cannabidiol; corresponding change to permit requirements","volume":"83","year":"2018","journal-title":"Final order. Federal register"},{"key":"B7","year":"2018"},{"key":"B8","volume-title":"Hemp Production and the 2018 Farm Bill","author":"Abernethy","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ajem.2021.06.066","article-title":"The current state of delta-8 THC","volume":"56","author":"Johnson-Arbor","year":"2022","journal-title":"Am J Emerg Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-021-00115-8","article-title":"Delta-8-THC: delta-9-THC's nicer younger sibling?","volume":"4","author":"Kruger","year":"2022","journal-title":"J Cannabis Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1111\/bph.15865","article-title":"Review of delta-8-tetrahydrocannabinol (\u03948-THC): comparative pharmacology with \u03949-THC","volume":"179","author":"Tagen","year":"2022","journal-title":"Br J Pharmacol."},{"key":"B12","first-page":"109","article-title":"Benefits and risks associated with cannabis and cannabis derivatives use","volume":"27","author":"Santo Gratteri","year":"2017","journal-title":"Confinia Cephalalgica"},{"key":"B13","unstructured":"BoosTL\n          Alabama Board of PharmacyDEA Letter to AL Board of Pharmacy2021"},{"key":"B14","volume-title":"CBD Oracle Lab Study Shows Some Delta-8 Products Are 7700% Over the Legal Delta-9 THC Limit","author":"Johnson","year":"2021"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/adaw.33199","article-title":"CDC and FDA warn of delta-8 THC harms","volume":"33","author":"Knopf","year":"2021","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"B16","first-page":"A1148","volume-title":"Novel Delta-8-Tetrahydrocannabinol Vaporizers Contain Unlabeled Adulterants, Byproducts of Chemical Synthesis, and Heavy Metals","author":"Meehan-Atrash","year":"2022"},{"key":"B17","volume-title":"Increases in Availability of Cannabis Products Containing Delta-8 THC and Reported Cases of Adverse Events","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103557","DOI":"10.1016\/j.drugpo.2021.103557","article-title":"Public interest in \u03948-tetrahydrocannabinol (delta-8-THC) increased in US states that restricted \u03949-tetrahydrocannabinol (delta-9-THC) use","volume":"101","author":"Leas","year":"2022","journal-title":"Int J Drug Policy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/dta.3190","article-title":"Analytical and medico-legal problems linked to the presence of delta-8-tetrahydrocannabinol (delta-8-THC): results from urine drug testing in Sweden","volume":"14","author":"Helander","year":"2022","journal-title":"Drug Test Anal."},{"key":"B20","unstructured":"ScientificT\n          CEDIA Multi-Level THC Assay"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e933488","DOI":"10.12659\/AJCR.933488","article-title":"Sedation and acute encephalopathy in a pediatric patient following ingestion of delta-8-tetrahydrocannabinol gummies","volume":"22","author":"Akpunonu","year":"2021","journal-title":"Am J Case Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100028","DOI":"10.1016\/j.psycr.2022.100028","article-title":"Marijuana variant of concern: delta 8-tetrahydrocannabinol (delta-8-THC, \u03948-THC)","volume":"1","author":"Bozman","year":"2022","journal-title":"Psychiatry Res Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1038\/sj.ijo.0803273","article-title":"Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength","volume":"30","author":"Mackie","year":"2006","journal-title":"Int J Obes."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.7150\/ijms.27087","article-title":"Cannabinoids: from pot to lab","volume":"15","author":"Papaseit","year":"2018","journal-title":"Int J Med Sci."},{"key":"B25","first-page":"109","article-title":"The phytocannabinoides from Cannabis sativa L. An overview","volume":"27","author":"Daniela","year":"2020","journal-title":"Hop Med Plants"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","article-title":"Endocannabinoids and their pharmacological actions","volume":"231","author":"Pertwee","year":"2015","journal-title":"Endocannabinoids"},{"key":"B27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 cannabinoid receptors as a therapeutic target\u2014what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euroneuro.2020.11.019","article-title":"Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1-and CB2-knockout mice","volume":"43","author":"Li","year":"2021","journal-title":"Eur Neuropsychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0028-3908(87)90035-9","article-title":"Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana","volume":"26","author":"Howlett","year":"1987","journal-title":"Neuropharmacology."},{"key":"B30","first-page":"705","article-title":"Marihuana: harvey lecture, February 19, 1942","volume":"18","author":"Adams","year":"1942","journal-title":"Bull N Y Acad Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpt1973143353","article-title":"Delta-8-and delta-9-tetrahydrocannabinol; comparison in man by oral and intravenous administration","volume":"14","author":"Hollister","year":"1973","journal-title":"Clin Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0301-0082(98)00087-2","article-title":"The effects of cannabinoids on the brain","volume":"58","author":"Ameri","year":"1999","journal-title":"Prog Neurobiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"107374","DOI":"10.1016\/j.addbeh.2022.107374","article-title":"Delta-8 THC use in US adults: sociodemographic characteristics and correlates","volume":"133","author":"Livne","year":"2022","journal-title":"Addict Behav"},{"key":"B35","volume-title":"Things to Know about Delta-8 Tetrahydrocannabinol\u2013Delta-8 THC.","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0074-7742(06)78010-2","article-title":"Cannabinoids and psychosis","volume":"78","author":"D'Souza","year":"2007","journal-title":"Int Rev Neurobiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.biopsych.2015.08.001","article-title":"Association between cannabis and psychosis: epidemiologic evidence","volume":"79","author":"Gage","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fpsyt.2014.00054","article-title":"Gone to pot\u2013a review of the association between cannabis and psychosis","volume":"5","author":"Radhakrishnan","year":"2014","journal-title":"Front Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","article-title":"Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review","volume":"73","author":"Volkow","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","article-title":"Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study","volume":"325","author":"Zammit","year":"2002","journal-title":"BMJ."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4088\/JCP.16f10918","article-title":"Cannabis and neuropsychiatry, 2: the longitudinal risk of psychosis as an adverse outcome","volume":"77","author":"Andrade","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005053-199008000-00001","article-title":"Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences","volume":"178","author":"Tien","year":"1990","journal-title":"J Nerv Ment Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15504263.2019.1674991","article-title":"Cannabis use and the risk for psychosis and affective disorders","volume":"16","author":"Sideli","year":"2020","journal-title":"J Dual Diagn."},{"key":"B44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamapsychiatry.2018.2546","article-title":"Genetic predisposition vs individual-specific processes in the association between psychotic-like experiences and cannabis use","volume":"76","author":"Karcher","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/0269881105049040","article-title":"Cannabis as a risk factor for psychosis: systematic review","volume":"19","author":"Semple","year":"2005","journal-title":"J Psychopharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1600-0447.1989.tb10296.x","article-title":"Schizophrenia in users and nonusers of cannabis: a longitudinal study in Stockholm County","volume":"79","author":"Andr\u00e9asson","year":"1989","journal-title":"Acta Psychiatr Scand."},{"key":"B47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1192\/bjp.187.6.510","article-title":"Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases","volume":"187","author":"Arendt","year":"2005","journal-title":"Br J Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"BMJ."},{"key":"B49","doi-asserted-by":"publisher","first-page":"E2657","DOI":"10.1073\/pnas.1206820109","article-title":"Persistent cannabis users show neuropsychological decline from childhood to midlife","volume":"109","author":"Meier","year":"2012","journal-title":"Proc Nat Acad Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamapsychiatry.2018.0335","article-title":"Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis","volume":"75","author":"Scott","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/dta.1506","article-title":"The adverse health effects of chronic cannabis use","volume":"6","author":"Hall","year":"2014","journal-title":"Drug Test Anal."},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0447.1990.tb01350.x","article-title":"Hallucinations in schizophrenia","volume":"82","author":"Mueser","year":"1990","journal-title":"Acta Psychiatr Scand."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1093\/schbul\/sbu036","article-title":"Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease","volume":"40","author":"Waters","year":"2014","journal-title":"Schizophr Bull"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/oalib.1107132","article-title":"Current trends in the use of cannabis sativa: beyond recreational and medicinal applications","volume":"8","author":"Omare","year":"2021","journal-title":"Open Access Libr J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature20153","article-title":"The effects of \u03949-tetrahydrocannabinol on the dopamine system","volume":"539","author":"Bloomfield","year":"2016","journal-title":"Nature."},{"key":"B56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1192\/bjp.bp.107.046375","article-title":"Effects of cannabis use on outcomes of psychotic disorders: systematic review","volume":"193","author":"Zammit","year":"2008","journal-title":"Br J Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1192\/bjp.189.2.102","article-title":"Aripiprazole for schizophrenia: systematic review","volume":"189","author":"El-Sayeh","year":"2006","journal-title":"Br J Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1103123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:25:14Z","timestamp":1676877914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1103123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":58,"alternative-id":["10.3389\/fpsyt.2023.1103123"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1103123","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"article-number":"1103123"}}